Mode
Text Size
Log in / Sign up
Phase 4 N=62 Randomized Single-blind Treatment

Quality of Recovery After Reversal With Neostigmine or Sugammadex.

Incomplete Reversal of Neuromuscular Block

Enrolled (actual)
62
Serious AEs
0.0%
Results posted
May 2020
Primary outcome: Primary: Incentive Spirometry, Change From Baseline and Recovery Profile - 30 Minutes — -700; -862 mL

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Sugammadex (Drug); Neostigmine (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Stony Brook University
Primary completion
Nov 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Incentive Spirometry, Change From Baseline and Recovery Profile - 30 Minutes
-700; -862
PRIMARY
Incentive Spirometry, Change From Baseline and Recovery Profile - 60 Minutes
-500; -1150
PRIMARY
Incentive Spirometry, Change From Baseline and Recovery Profile - 120 Minutes
-400; -850
SECONDARY
Grip Strength, Change From Baseline and Recovery Profile 30 Min
24.15; 21.38
SECONDARY
Grip Strength, Change From Baseline and Recovery Profile 60 Min
12.68; 17.69
SECONDARY
Grip Strength, Change From Baseline and Recovery Profile 120 Min
7.84; 11.85
SECONDARY
Time to Extubation
8; 7
SECONDARY
Train of Four Ratio > 90% During PACU Admission
25; 25
SECONDARY
Quality of Recovery 15 Survey
117; 105
SECONDARY
Time to Readiness for Post Anesthesia Care Unit (PACU) Discharge (Aldrete Score >9)
109; 112

Summary

This study will compare patient recovery measures after reversal of neuromuscular blockade with neostigmine or sugammadex after surgery. Measures include pulmonary function, muscle strength, time to extubation and quality of recovery in the post anesthesia care unit.

Eligibility Criteria

Inclusion Criteria

  • Participant must be willing and able to provide written informed consent for the study
  • Participant must be greater than or equal to 18 years of age
  • Participant must be ASA (American Society of Anesthesiologists) class I, II or III
  • Planned use of neuromuscular blocking drugs
  • Planned use of endotracheal intubation
  • Planned for extubation to occur in the OR

Exclusion Criteria

  • ASA (American Society of Anesthesiologists) Class IV
  • Age < 18 years old
  • Inability to give oral or written consent
  • Known or suspected neuromuscular disorder impairing neuromuscular function
  • True allergy to muscle relaxants
  • A (family) history of malignant hyperthermia
  • A contraindication for neostigmine or sugammadex administration
  • Serum creatinine level of greater than 2.0 mg/dL
  • Surgery where the patient's arm is not available for neuromuscular monitoring
  • A plan to extubate under deep anesthesia
  • Pregnant
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02909439). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search